Pfizer/BioNtech's COVID-19 Shot Staved Off Illness, Death For Over 95% Of Israeli patients

The Israel health ministry said that Pfizer Inc (NYSE: PFE) and BioNtech SE's (NASDAQ: BNTX) COVID-19 vaccine had proved 95.8% effective in preventing coronavirus infection among those vaccinated two weeks after receiving their second shot, compared to unvaccinated people, according to data compiled up to February 13.
The shot appeared to stop the vast majority of vaccine recipients in Israel from COVID-19 infection, providing the first real-world indication that the immunization will curb transmission of the coronavirus, the health ministry reported.
The results showed that the vaccine was 89% effective at preventing infection of any kind and 98.9% effective in preventing hospitalizations and death, and 94% effective against symptomatic infection.
The latest data has not yet been peer-reviewed, though some scientists disputed its accuracy.
The Health Ministry has also rolled out a "Green Pass" app linked to personal medical files. People who have been fully inoculated or deemed immune after recovering from COVID-19 can show to stay at hotels or attend cultural or sporting events.
Price Action: PFE is up 0.3% at $34.53, and BNTX is up 1.3% at $117.2 in premarket trading on last check Monday.